Because others have reported that TGFβ inhibition has an anti‐tumor effect in vivo in models of breast cancer and myeloma,39, 40, 41 we wanted to discount that any effect we observed was due to a reduction in tumor burden. This evidence concerns the gene TGFB1 and plasma cell myeloma.